{"prompt": "['Alliance A171601', 'efficacy of cytostatic agents, such as endocrine therapy or HER2-targeted therapy, but', 'decreases the efficacy of cytotoxic chemotherapy such as with carboplatin and doxorubicin', '110-112 Clinical trials have shown significant benefit in progression free survival for women', 'with metastatic breast cancer on palbociclib with or without prior AI (letrozole) or', 'fulvestrant treatment. The variation in median PFS among the patients have ranged from', '10.2 months (95 % CI, 5.7-12.6) for the letrozole group to 20.2 months (95% CI, 13.8-', '27.5) for the palbociclib-letrozole group suggesting that other factors associated with', 'palbociclib could be contributing to the clinical outcomes. 105 Similar PFS trends were seen', 'in the study of palbociclib with/without fulvestrant 106,107', 'Turner et al.', '106', 'reported a median', 'PFS of 9.2 months (95% CI, 7.5-not estimable) for palbociclib-fulvestrant group and 3.8', 'months (95 % CI, 3.5-5.5) for the placebo-fulvestrant group, 106, while Cristofanilli et', 'al107 reported a median PFS of 9.5 months (95% CI, 9.2-11.0) in thepalbociclib-fulvestrant', 'group and 4.6 months (95% CI, 3.5-5.6) in the placebo-fulvestrant group.', 'All of these trials have shown variations in the clinical outcomes 105-107 One factor that could', 'in part explain some of these variations might be the role of inherited genetic variants whose', 'proteins may be responsible for the biotrans formation of the AIs, fulvestrant and palbocio lib.', 'Several reports on candidate genes and genome wide association studies (GWAS) have', 'correlated single nucleotide polymorphisms (SNP) in the estrogen metabolism related', 'pathway genes with response to endocrine therapy for breast cancer. 114-118 To date, there is', 'no study that has looked at genetic variants associated with palbociclib biotrans formation', 'pathway genes with response to the treatment in metastatic breast cancer, let alone elucidate', 'how these polymorphisms are associated with tolerability and response to palbocic lib', 'therapy in the elderly, specifically women aged 70 years and over. This proposal plans to', 'elucidate the genetic determinants of palbociclib efficacy in post-menopausal women with', 'metastatic HR positive, HER2 negative breast cancers undergoing treatment in the parent', 'study.', 'Palbociclib metabolism, cell cycle proteins, genes and genetic variants : Palbociclib is', 'primarily metabolized by CYP3A enzyme and undergoes sulfonation by SULT2A1 enzyme', 'and undergoes acylation and glucuronidation as minor metabolic patheways 109, 119-121', 'Palbociclib is also a highly selective inhibitor of CDK4 and CDK6 kinases and in low', 'nanomolar concentrations blocks retinoblastoma (Rb) gene protein product pRb. 108', 'Cyclin-dependent kinases (CDKs) are serine/threonine kinases that play a key role in', 'regulating cell cycle progression by associating with cyclins. The cell cycle is a tightly', 'regulated process of five distinct phases: GO (quiescence) followed by G1 (pre-DNA', 'synthesis), S (DNA synthesis), G2 (pre-division) and M (cell division) with the G1 to S', 'phase being the key checkpoint in protecting the cell from abnormal replication.', '108', 'CDK4', 'and CDK6 interact with cyclin D1 early in this checkpoint phase resulting in the', 'phosphorylation of pRb and allowing the release of transcription factor E2F which leads to', 'transcription of other target genes to allow progression to the S phase. 108 CDK activity is', 'thus tightly regulated at severallevels by Cyclin D and retinoblastoma proteins and by CDK', 'inhibitory proteins the INK4 family (p16, p15, p18, p19) and CIP/KIP family (p21, p27,', 'p57). 122-124 Thus when the cell cycle regulatory mechanism is altered, uncontrolled cell', 'proliferation occurs which is a distinctive feature of human cancers. 125', 'Cell cycle genes, polymorphisms and cancer: Many of the genes encoding the cell cycle', 'proteins are frequently mutated in human cancers and this leads to uncontrolled cell division', 'and tumor growth as well. 126 For instance, in breast cancer, alterations in cell cycle', 'regulators have been reported to include amplification of cyclin D1 gene (15-20% cancers)', 'and overexpression of its protein product which has been associated with poor clinical', 'outcomes, to indolent estrogen receptor positive phenotype and to tamoxifen resistance', '68', 'NCI Version Date: 5/29/2020', 'Update 5']['Alliance A171601', 'cycl lin D protein. 108,127-132 Furthermore, studies have been reported that show that inhibiting', 'CDK4 and CDK6 kinases induce G1 arrest in sensitive cell lines and primary bone marrow', 'cells and prevent tumor growth in human myeloma xenografts. 133-137', 'The genes encoding the proteins involved in the G1-S phase include CCNDI[cyclin D1],', 'CCND2 [cyclin D2], CCND3 [cyclin D3], CCNEI [cyclin E] (the cyclin family which', 'regulate cyclin-dependent kinases); CDK2 [p33], CDK4, and CDK6 (cyclin-dependent', 'kinases for the G1/S transition); CDKNIA [p21, Cip1], CDKNIB [p27, Kip1] (CIP/KIP', 'family cyclin-dependent kinase inhibitors); CDKN2A [p16], CDKN2B [p15], CDKN2C', '[p18], and CDKN2D [p19] (INK4 family cyclin-dependent kinase inhibitors) and RBI', 'retinoblastoma gene. Studies relating to genetic polymorphisms in cell cycle genes and risk', 'of some cancers including lung, bladder, prostate, breast, ovarian, endometrial, pancreas,', 'and colorectal\u00b9 138-145 have been published although none have taken into consideration the', 'effects these inherited genetic variations may have on the efficacy of palbociclit which', 'specifically inhibits the CDK4/6 check point.', 'In breast cancer studies, polymorphisms such as CDKNIB rs2066827 has been associated', 'with shortened disease-free survival in patients with infiltrating metastasis-free breast', 'cancer146 while CCND3 rs2479717 has been associated with an increased risk of death. 147', 'Other SNPs including CCNE. 1 rs997669, CDKNIA rs3176336, CDKNIB rs34330,', 'CDKN2B rs3218005 and CDKN2A rs3731239 have been associated with breast cancer as', 'well. 148 CCNDI rs9344 (CCND1-02 A870G or CCNDI G870A) the most studied SNP in', 'CCNDI and previously referred to as CCND1 rs603965 has been shown to be associated', 'with breast cancer survival in Chinese subjects, 149 and has also been associated with breast', 'cancer risk and poorer breast cancer specific survival in patients with metastatic breast', 'cancer. 15-152 Polymorphisms in CYP3A4 1153,154 and in SULT2A1 155,156 have', 'also', 'been', 'associated with breast and other cancers.', 'These associations of the cell cycle gene SNPs with breast cancer may be influenced by', \"palbociclib's action of inhibiting CDK4/6 in the G1-S transition point thereby modifying\", 'clinical response and toxicity outcomes. This study is ideal to elucidate the associations of', 'cell cycle SNPs in the presence of palbociclib on breast cancer in the elderly. We note that', 'polymorphisms in aromatase CYP19A, CYP2A6 and estrogen receptor ERSI genes 157-160', 'the targets for AI inhibitors and fulvestrant respectively, have also been associated with', 'breast cancer. Therefore SNPs in these 2 genes under the influence of their specific', 'inhibitors combined with palbociclib in the treatment (choice of AI or fulvestrant made at', 'the discretion of the treating investigator) will be studied for associations with clinical', 'response and toxicity to palbociclib Furthermore, the genetic variants in palbociclib related', 'genes will be correlated with the primary objective of the study which includes tolerability', '(adverse events); and with the secondary objectives which include toxicity, response to', 'treatment, and overall survival.', 'We hypothesize that inherited genetic polymorphisms in cell cycle pathway genes and in', 'genes that metabolize palbociclib will correlate with clinical outcomes in elderly patients', 'undergoing palbociclib treatment for estrogen receptor positive, HER2 negative metastatic', 'breast cancer. We further hypothesize that genes in CYP19A1, CYP2A6 and ESR1 will also', 'correlate will toxicity outcomes in this study.', 'We propose to achieve this hypothesis by genotyping patient DNA samples for SNPs in the', 'cell cycle genes including CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6,', 'CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CDKN2D, CYP3A4,', 'CYP19A1, CYP2A6, ESRI RB1 and SULT2A1 and correlate these SNPs to efficacy and', 'toxicity of palbociclib.', '69', 'NCI Version Date: 5/29/2020', 'Update 5']\n\n###\n\n", "completion": "END"}